Xeomin Botulinum Toxin Injections

Birmingham AL Xeomin Treatments for Temporary Frown Line Reduction

If you have moderate-to-severe glabellar lines (frown lines between the eyebrows), Xeomin might be the right choice for you. Xeomin^® contains Botulinum Toxin Type A, which acts on nerve endings and muscles to prevent the contraction of muscle fibers. Xeomin was FDA-approved for aesthetic use in 2011 based on clinical trials.

Wrinkle Treatments with Xeomin

When you frown or squint, the muscles between your brows contract and cause the skin to furrow and fold. These repeated contractions can cause persistent frown lines over time as your skin ages and begins to lose its elasticity. By reducing these muscle contractions, Xeomin (incobotulinumtoxinA) is used to temporarily improve the appearance of moderate-to-severe frown lines between the eyebrows in adults.

During Birmingham, Alabama Xeomin treatments at Hedden & Gunn Plastic Surgery, your physician injects Xeomin into the muscles in your forehead that cause frown lines between the brows. Treatments with Xeomin usually take only about 10 to 20 minutes and can be conveniently performed during a lunch hour.

During clinical trials, some patients saw visible smoothing as soon as 3 to 4 days following treatment with Xeomin. The median first onset of results was less than a week, with the maximum effect occurring at 30 days. The typical duration of results was up to 3 months in the clinical trials, but may last significantly longer or shorter for individual patients.

Xeomin Safety

XEOMIN is a prescription medicine that is injected into muscles and used to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults for a short period of time (temporary). XEOMIN is contraindicated in patients with known hypersensitivity to any botulinum toxin product or to any of the components in the formulation, and in patients with an infection at the proposed injection site(s) because it could lead to severe local or disseminated infection.